Spots Global Cancer Trial Database for Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Official Title: A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer
Study ID: NCT00842998
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion biological study will assess factors correlated with sensitivity or resistance to either one of the compounds
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
U.O. Oncologia Medica - Ospedale San Luigi, Orbassano, Torino, Italy
Institute for Cancer Research and Treatment (I.R.C.C.), Candiolo , Torino, , Italy
U.O. Oncologia Medica, Cuneo, , Italy
U.O. Oncologia Medica - COES Molinette, Torino, , Italy
Contact Details
Name: Massimo Aglietta, Full Professor, MD
Affiliation: University of Turin Medical School at AO Ordine Mauriziano di Torino
Role: STUDY_CHAIR
Name: Filippo Montemurro, MD
Affiliation: AO Ordine Mauriziano di Torino
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
